Alnylam's RSV Therapy in Limbo After Phase IIb Miss

The future of Alnylam Pharmaceuticals Inc.'s RNAi candidate for respiratory syncytial virus (RSV), ALN-RSV01, could be either continued development or total termination, according to CEO John Maraganore, following the drug's failure to hit its primary endpoint in a Phase IIb trial against progressive bronchiolitis obliterans syndrome (BOS) in lung transplant patients.